A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers

Trial Profile

A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Olaparib (Primary) ; Carboplatin
  • Indications Breast cancer; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 01 Jul 2017 Results of a population pharmacokinetic analyses (n = 58) published in the Cancer Chemotherapy and Pharmacology
    • 04 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top